Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.48
18.53
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Yantai Dongcheng Biochemicals Co Ltd
Gross Profit
Yantai Dongcheng Biochemicals Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Y
|
Yantai Dongcheng Biochemicals Co Ltd
SZSE:002675
|
Gross Profit
¥1.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
18%
|
|
|
Beigene Ltd
HKEX:6160
|
Gross Profit
¥14.7B
|
CAGR 3-Years
108%
|
CAGR 5-Years
67%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Gross Profit
¥6.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Gross Profit
¥4.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Gross Profit
¥9.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
34%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Gross Profit
¥2.7B
|
CAGR 3-Years
61%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
Yantai Dongcheng Biochemicals Co Ltd
Glance View
In the bustling industrial city of Yantai, nestled along China's northeastern coast, Yantai Dongcheng Biochemicals Co Ltd has emerged as a formidable entity in the global biopharmaceutical landscape. Founded in 1998, the company has cleverly positioned itself at the confluence of modern science and traditional Chinese medicine. The hallmark of Dongcheng's business is its sophisticated production of active pharmaceutical ingredients (APIs), particularly heparin, which has earned it a prominent spot on the world stage. Through its agile manufacturing processes and commitment to quality, the company deftly navigates the intricate web of pharmaceutical demands, supplying essential components to global drug manufacturers who trust Dongcheng's expertise to ensure efficacy and safety in their final products. The financial engine of Yantai Dongcheng Biochemicals is powered by its vertically integrated model, which extends from raw material acquisition to finished product delivery. This strategic structure not only mitigates costs and enhances supply chain stability but also fortifies its competitive edge in the burgeoning healthcare market. The company has also expanded its portfolio to include a diverse array of biochemical products, catering to various therapeutic areas such as anticoagulation, oncology, and anti-infectives. This diversification not only spreads risk but also captures a broader spectrum of revenue opportunities. Moreover, Dongcheng's keen eye for innovation has seen it invest heavily in research and development, ensuring that it remains at the cutting edge of biopharmaceutical advancements. Through this strategic orchestration of resources and innovation, Dongcheng continues to deepen its footprint in the global market, underscoring its reputation as a trusted and dynamic player in the pharmaceutical industry.
See Also
What is Yantai Dongcheng Biochemicals Co Ltd's Gross Profit?
Gross Profit
1.3B
CNY
Based on the financial report for Sep 30, 2024, Yantai Dongcheng Biochemicals Co Ltd's Gross Profit amounts to 1.3B CNY.
What is Yantai Dongcheng Biochemicals Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
18%
Over the last year, the Gross Profit growth was -13%. The average annual Gross Profit growth rates for Yantai Dongcheng Biochemicals Co Ltd have been -5% over the past three years , -5% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
